{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:43:51Z","timestamp":1793227431223,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["252300420125"],"award-info":[{"award-number":["252300420125"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303914"],"award-info":[{"award-number":["82303914"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29305-7","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:45:26Z","timestamp":1764251126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exosomal miR-20a-5p derived from cisplatin-resistant osteosarcoma cells promotes chemoresistance via Inhibition of ferroptosis through targeting RUNX3"],"prefix":"10.1038","volume":"15","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyue","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"29305_CR1","unstructured":"Board, P. D. Q. P. T. E. In PDQ Cancer Information Summaries (National Cancer Institute (US), 2002)."},{"issue":"Suppl 2","key":"29305_CR2","doi-asserted-by":"publisher","first-page":"e28352","DOI":"10.1002\/pbc.28352","volume":"68","author":"BR Eaton","year":"2021","unstructured":"Eaton, B. R. et al. Osteosarcoma. Pediatr. Blood Cancer. 68(Suppl 2), e28352. https:\/\/doi.org\/10.1002\/pbc.28352 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"29305_CR3","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra2103423","volume":"385","author":"PS Meltzer","year":"2021","unstructured":"Meltzer, P. S. & Helman, L. J. New horizons in the treatment of osteosarcoma. N. Engl. J. Med. 385, 2066\u20132076. https:\/\/doi.org\/10.1056\/NEJMra2103423 (2021).","journal-title":"N. Engl. J. Med."},{"key":"29305_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11912-021-01053-7","volume":"23","author":"R Belayneh","year":"2021","unstructured":"Belayneh, R., Fourman, M. S., Bhogal, S. & Weiss, K. R. Update on osteosarcoma. Curr. Oncol. Rep. 23, 71. https:\/\/doi.org\/10.1007\/s11912-021-01053-7 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"29305_CR5","doi-asserted-by":"publisher","first-page":"154743","DOI":"10.1016\/j.prp.2023.154743","volume":"249","author":"M Moghbeli","year":"2023","unstructured":"Moghbeli, M. MicroRNAs as the pivotal regulators of cisplatin resistance in osteosarcoma. Pathol. Res. Pract. 249, 154743. https:\/\/doi.org\/10.1016\/j.prp.2023.154743 (2023).","journal-title":"Pathol. Res. Pract."},{"key":"29305_CR6","doi-asserted-by":"publisher","first-page":"216261","DOI":"10.1016\/j.canlet.2023.216261","volume":"567","author":"W Jia","year":"2023","unstructured":"Jia, W., Yuan, J., Cheng, B. & Ling, C. Targeting tumor-derived exosome-mediated premetastatic niche formation: the metastasis-preventive value of traditional Chinese medicine. Cancer Lett. 567, 216261. https:\/\/doi.org\/10.1016\/j.canlet.2023.216261 (2023).","journal-title":"Cancer Lett."},{"key":"29305_CR7","doi-asserted-by":"publisher","unstructured":"Wang, M. et al. Exosome as a crucial communicator between tumor microenvironment and gastric cancer (Review). Int. J. Oncol. 64. https:\/\/doi.org\/10.3892\/ijo.2024.5616 (2024).","DOI":"10.3892\/ijo.2024.5616"},{"key":"29305_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12951-024-02634-x","volume":"22","author":"Z Iqbal","year":"2024","unstructured":"Iqbal, Z. et al. Exosome for mRNA delivery: strategies and therapeutic applications. J. Nanobiotechnol. 22, 395. https:\/\/doi.org\/10.1186\/s12951-024-02634-x (2024).","journal-title":"J. Nanobiotechnol."},{"key":"29305_CR9","doi-asserted-by":"publisher","first-page":"117278","DOI":"10.1016\/j.ejmech.2025.117278","volume":"285","author":"Z Tang","year":"2025","unstructured":"Tang, Z. et al. Insights into tumor-derived exosome Inhibition in cancer therapy. Eur. J. Med. Chem. 285, 117278. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117278 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"29305_CR10","doi-asserted-by":"publisher","unstructured":"Martinez-Espinosa, I., Serrato, J. A. & Ortiz-Quintero, B. The role of exosome-derived microRNA on lung cancer metastasis progression. Biomolecules 13 https:\/\/doi.org\/10.3390\/biom13111574 (2023).","DOI":"10.3390\/biom13111574"},{"key":"29305_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12929-024-01055-0","volume":"31","author":"YF Chen","year":"2024","unstructured":"Chen, Y. F., Luh, F., Ho, Y. S. & Yen, Y. Exosomes: a review of biologic function, diagnostic and targeted therapy applications, and clinical trials. J. Biomed. Sci. 31, 67. https:\/\/doi.org\/10.1186\/s12929-024-01055-0 (2024).","journal-title":"J. Biomed. Sci."},{"key":"29305_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12943-018-0897-7","volume":"17","author":"Z Sun","year":"2018","unstructured":"Sun, Z. et al. Effect of Exosomal MiRNA on cancer biology and clinical applications. Mol. Cancer. 17, 147. https:\/\/doi.org\/10.1186\/s12943-018-0897-7 (2018).","journal-title":"Mol. Cancer"},{"key":"29305_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12951-019-0563-2","volume":"18","author":"G Liang","year":"2020","unstructured":"Liang, G. et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J. Nanobiotechnol. 18, 10. https:\/\/doi.org\/10.1186\/s12951-019-0563-2 (2020).","journal-title":"J. Nanobiotechnol."},{"key":"29305_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10565-021-09685-y","volume":"39","author":"S Cao","year":"2023","unstructured":"Cao, S. et al. Linc00852 from cisplatin-resistant gastric cancer cell-derived exosomes regulates COMMD7 to promote cisplatin resistance of recipient cells through microRNA-514a-5p. Cell Biol. Toxicol. 39, 483\u2013496. https:\/\/doi.org\/10.1007\/s10565-021-09685-y (2023).","journal-title":"Cell Biol. Toxicol."},{"key":"29305_CR15","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.2147\/ijn.S131516","volume":"12","author":"X Qin","year":"2017","unstructured":"Qin, X. et al. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in Exosomal miR-100-5p-dependent manner. Int. J. Nanomed. 12, 3721\u20133733. https:\/\/doi.org\/10.2147\/ijn.S131516 (2017).","journal-title":"Int. J. Nanomed."},{"key":"29305_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang, C., Liu, X., Jin, S., Chen, Y. & Guo, R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol. Cancer. 21, 47. https:\/\/doi.org\/10.1186\/s12943-022-01530-y (2022).","journal-title":"Mol. Cancer"},{"key":"29305_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266\u2013282. https:\/\/doi.org\/10.1038\/s41580-020-00324-8 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"29305_CR18","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.drup.2022.100916","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist. Updates: Reviews Commentaries Antimicrob. Anticancer Chemother. 66, 100916. https:\/\/doi.org\/10.1016\/j.drup.2022.100916 (2023).","journal-title":"Drug Resist. Updates: Reviews Commentaries Antimicrob. Anticancer Chemother."},{"key":"29305_CR19","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1038\/s41467-021-25354-4","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu, W. et al. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nat. Commun. 12, 5103. https:\/\/doi.org\/10.1038\/s41467-021-25354-4 (2021).","journal-title":"Nat. Commun."},{"key":"29305_CR20","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13046-021-01901-1","volume":"40","author":"Q Yang","year":"2021","unstructured":"Yang, Q. et al. Chemotherapy-elicited Exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2\/STAT3 signaling. J. Experimental Clin. Cancer Research: CR. 40, 120. https:\/\/doi.org\/10.1186\/s13046-021-01901-1 (2021).","journal-title":"J. Experimental Clin. Cancer Research: CR"},{"key":"29305_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41416-022-02077-x","volume":"128","author":"S Zhao","year":"2023","unstructured":"Zhao, S. et al. Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer. Br. J. Cancer. 128, 665\u2013677. https:\/\/doi.org\/10.1038\/s41416-022-02077-x (2023).","journal-title":"Br. J. Cancer"},{"key":"29305_CR22","doi-asserted-by":"publisher","first-page":"101211","DOI":"10.1016\/j.drup.2025.101211","volume":"79","author":"YY Yan","year":"2025","unstructured":"Yan, Y. Y. et al. Low miR-224-5p in exosomes confers colorectal cancer 5-FU resistance by upregulating S100A4. Drug Resist. Updates: Reviews Commentaries Antimicrob. Anticancer Chemother. 79, 101211. https:\/\/doi.org\/10.1016\/j.drup.2025.101211 (2025).","journal-title":"Drug Resist. Updates: Reviews Commentaries Antimicrob. Anticancer Chemother."},{"key":"29305_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-016-0340-3","volume":"16","author":"Y Pu","year":"2016","unstructured":"Pu, Y. et al. MiR-20a-5p represses multi-drug resistance in osteosarcoma by targeting the KIF26B gene. Cancer Cell Int. 16, 64. https:\/\/doi.org\/10.1186\/s12935-016-0340-3 (2016).","journal-title":"Cancer Cell Int."},{"key":"29305_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12935-017-0470-2","volume":"17","author":"F Zhao","year":"2017","unstructured":"Zhao, F., Pu, Y., Cui, M., Wang, H. & Cai, S. MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene. Cancer Cell Int. 17, 100. https:\/\/doi.org\/10.1186\/s12935-017-0470-2 (2017).","journal-title":"Cancer Cell Int."},{"key":"29305_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/cas.16036","volume":"115","author":"W Li","year":"2024","unstructured":"Li, W. et al. Cancer cell-derived Exosomal miR-20a-5p inhibits CD8(+) T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer. Cancer Sci. 115, 347\u2013356. https:\/\/doi.org\/10.1111\/cas.16036 (2024).","journal-title":"Cancer Sci."},{"key":"29305_CR26","doi-asserted-by":"publisher","first-page":"115933","DOI":"10.1016\/j.bcp.2023.115933","volume":"219","author":"X Zhang","year":"2024","unstructured":"Zhang, X., Li, X., Xia, R. & Zhang, H. S. Ferroptosis resistance in cancer: recent advances and future perspectives. Biochem. Pharmacol. 219, 115933. https:\/\/doi.org\/10.1016\/j.bcp.2023.115933 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"29305_CR27","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","volume":"35","author":"B Hassannia","year":"2019","unstructured":"Hassannia, B. & Vandenabeele, P. Vanden Berghe, T. Targeting ferroptosis to iron out cancer. Cancer cell. 35, 830\u2013849. https:\/\/doi.org\/10.1016\/j.ccell.2019.04.002 (2019).","journal-title":"Cancer cell."},{"key":"29305_CR28","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2024.0882","author":"B Fan","year":"2025","unstructured":"Fan, B., Wang, L., Hu, T., Zheng, L. & Wang, J. Exosomal miR-196a-5p secreted by bone marrow mesenchymal stem cells inhibits ferroptosis and promotes drug resistance of acute myeloid leukemia. Antioxid. Redox. Signal. https:\/\/doi.org\/10.1089\/ars.2024.0882 (2025).","journal-title":"Antioxid. Redox. Signal."},{"key":"29305_CR29","doi-asserted-by":"publisher","first-page":"119399","DOI":"10.1016\/j.lfs.2021.119399","volume":"276","author":"Z Song","year":"2021","unstructured":"Song, Z., Jia, G., Ma, P. & Cang, S. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis. Life Sci. 276, 119399. https:\/\/doi.org\/10.1016\/j.lfs.2021.119399 (2021).","journal-title":"Life Sci."},{"key":"29305_CR30","doi-asserted-by":"publisher","first-page":"113804","DOI":"10.1016\/j.intimp.2024.113804","volume":"146","author":"H Han","year":"2025","unstructured":"Han, H. et al. Exosomal miR-130a-3p confers cisplatin resistance in esophageal cancer by regulating ferroptosis via the suppression of METTL14-mediated m6A RNA methylation of FSP1. Int. Immunopharmacol. 146, 113804. https:\/\/doi.org\/10.1016\/j.intimp.2024.113804 (2025).","journal-title":"Int. Immunopharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29305-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29305-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29305-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:10:52Z","timestamp":1777129852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29305-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29305"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29305-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Henan Cancer Hospital (2022-200-001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"45441"}}